DAC:Opioid: CJC completed enrollment in 2 Phase II trials of its intravenous CJC-1008. Both studies were placebo-controlled, double-blinded, and enrolled about

ConjuChem Inc. (TSE:CJC), Montreal, Quebec
Product: DAC:Opioid (CJC-1008)
Business: Neurological
Therapeutic category: Receptor agonist

Read the full 148 word article

How to gain access

Continue reading with a
two-week free trial.